" Oncolytics Biotech (TSX:ONC) advances Chinese cancer trial

Oncolytics Biotech (ONC) partner, Adlai Nortye, reported results from a clinical evaluation of pelareorep-paclitaxel combination therapy for advanced breast cancer.

" BriaCell (TSX:BCT) releases positive clinical and quality of life data in advanced metastatic breast cancer study

BriaCell Therapeutics (BCT) presented positive safety/tolerability and efficacy data from its lead product candidate, Bria-IMT.

" MCI Onehealth (TSX:DRDR) clinical data insights pipeline gains momentum

MCI Onehealth (DRDR) is evolving its tech and clinical data insights through revenue deals and relationships with businesses in health and life-sciences.

" Sirona Biochem (TSXV:SBM) begins clinical trial for anti-aging compound TFC-1326

Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326.
NurExone Biologic Inc - Lior Shaltiel, CEO & Director

" NurExone Biologic (TSXV:NRX) completes securities-for-debt settlement

NurExone Biologic (NRX) has completed its securities-for-debt settlement.

" Vitalhub (TSX:VHI) announces multi year contract with Coventry and Warwickshire ICB

VitalHub (VHI) subsidiary, Transforming Systems, signed a multi-year licensing contract with Coventry and Warwickshire Integrated Care Board in England.

" IntelGenx Corp. (TSX:IGX) collaborating with UPEI to evaluate VetaFilm in dogs & cats

IntelGenx (IGX) began a research collaboration with the University of Prince Edward Island to assess its VetaFilm platform in healthy dogs and cats.

" Marvel Biosciences (TSXV:MRVL) begins next milestone study for its lead asset targeting Alzheimer’s & Depression

Marvel (MRVL) has initiated its 7-day dose-ranging toxicology study for its lead molecule MB-204.

" BetterLife Pharma (CSE:BETR) closes private placement

BetterLife Pharma (BETR) has closed a non-brokered private placement for gross proceeds of $474,000.

" Titan Medical (TSX:TMD) furloughs workers to support strategic review process

Titan Medical (TMD) implemented cost-cutting measures in order to continue working on the investigational device exemption (IDE) filing with the FDA.

" MCI Onehealth (TSX:DRDR) supports Canadian employee well-being

MCI Onehealth Technologies (DRDR) is now a Canadian distributor for Virgin Pulse.
Tetra Bio-Pharma Inc - CEO & CRO, Dr. Guy Chamberland

" Tetra Bio-Pharma (TSX:TBP) AI study shows drug efficacy

Cannabinoid drug developer, Tetra Bio-Pharma (TBP), announced positive results from an artificial intelligence study.
Defence Therapeutics - President & CEO, Sébastien Plouffe

" Defence (CSE:DTC) advancing cancer treatment

Defence Therapeutics (DTC) has completed good laboratory studies related to its anti-cancer AccuTOX molecule and will move this work to a phase one trial.

" wellteq Digital Health Inc. (CSE:WTEQ) completes plan of arrangement with Advanced Human Imaging Ltd. (ASX:AHI)

wellteq Digital Health (WTEQ) has completed its plan of arrangement with Advanced Human Imaging Ltd. (AHI).
Reliq Health Technologies - CEO Dr. Lisa Crossley

" Reliq Health Technologies (TSXV:RHT) announces 35 new skilled nursing facilities clients in Florida

A Reliq Health (RHT) client with a network of Skilled Nursing Facilities in Florida has added an additional 35 facilities to its contract.
Global Wellness Strategies - CEO, Meris Kott

" Global Wellness (CSE:GWS) pharma subsidiary supporting cancer therapeutic company AVM Biotechnology

Global Wellness Strategies (GWS) is working with subsidiary BioMed360.

" VitalHub (TSX:VHI) announces multi-year contract with Black Country ICB

VitalHub (VHI) subsidiary, Transforming Systems, signed a multi-year licensing contract with Black Country Integrated Care Board (ICB).

" Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals (AGN) has been granted Orphan Drug Designation (ODD) for Ifenprodil to treat Idiopathic Pulmonary Fibrosis (IPF).

" SQI Diagnostics (TSXV:SQD) closes first tranche of private placement

SQI Diagnostics (SQD) has completed the first tranche of its non-brokered private placement.